VSV-IFNβ-NIS + Ipilimumab + Nivolumab for Kidney Cancer

This trial explores a new combination treatment for advanced or metastatic clear cell kidney cancer. Researchers are testing whether adding VSV-IFNβ-NIS, a lab-modified virus targeting cancer cells, to standard immune-based therapies (ipilimumab and nivolumab) can more effectively combat this cancer. The goal is to determine if this approach can enhance the immune system's ability to attack the cancer and prevent its spread. Individuals with advanced clear cell kidney cancer that cannot be treated with surgery or radiation might be suitable candidates for this trial. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants, offering a chance to contribute to significant advancements in cancer therapy.

The trial information does not specify if you need to stop taking your current medications. However, you cannot participate if you are receiving certain treatments like chemotherapy, immunotherapy, or radiotherapy, or if you have uncontrolled illnesses. It's best to discuss your specific medications with the trial team.

Previous studies have shown that VSV-IFNβ-NIS is safe and well-tolerated by patients. Research indicates that this treatment targets cancer cells without harming healthy ones. Clinical trials have not reported major safety concerns, suggesting it is generally safe for humans.

Researchers are excited about these treatments for kidney cancer because they combine innovative approaches to boost the immune system's fight against cancer. Unlike standard treatments, which often focus on surgery or radiation, this combination uses VSV-IFNβ-NIS, a modified virus designed to selectively attack cancer cells while sparing healthy ones, alongside the immune checkpoint inhibitors ipilimumab and nivolumab. These inhibitors work by unleashing the immune system to recognize and destroy cancer cells more effectively. This combined therapy could offer more precise targeting of cancer cells and potentially lead to better outcomes for patients.

Research has shown that using nivolumab and ipilimumab together effectively treats advanced kidney cancer. One study found that participants taking this combination had a 37% lower risk of death compared to those taking sunitinib. This combination is associated with longer survival and more lasting treatment effects. In this trial, participants will receive a combination of nivolumab, ipilimumab, and VSV-IFNβ-NIS. VSV-IFNβ-NIS is a promising new therapy that uses a virus to target and kill cancer cells while sparing normal cells. Early studies suggest that adding this virus could boost the immune system and help control cancer growth.¹²⁵⁶⁷